Lv51
802 积分 2025-01-23 加入
Prevalence of Targetable Mutations in Black Patients With Lung Cancer: A Systematic Review and Meta-Analysis
12分钟前
待确认
Osimertinib plus Gefitinib in Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARD
1个月前
已完结
Longitudinal Analyses of Circulating Tumor DNA for the Detection of EGFR Mutation-Positive Advanced NSCLC Progression During Treatment: Data From FLAURA and AURA3
1个月前
已完结
Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB–IIIA Non-Small Cell Lung Cancer: Exploratory 8-year Overall Survival Landmark Update from the ADAURA Trial [161/175]
1个月前
已完结
Efficacy and Safety of Firmonertinib Plus Anlotinib as First-Line Treatment for Advanced NSCLC With EGFR Mutations: A Single-Arm, Phase I/II Trial
2个月前
已完结
Osimertinib combined with anlotinib as first-line treatment in advanced or metastatic NSCLC patients with EGFR mutation: a prospective, single arm, exploratory study
2个月前
已完结
Sequential Afatinib and Osimertinib in Patients with EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Final Analysis of the GioTag Study
2个月前
已完结
Real-world osimertinib for EGFR mutation-positive non-small-cell lung cancer with acquired T790M mutation
2个月前
已完结
Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: final analysis of the GioTag study
2个月前
已关闭
Inhibition of oxidative phosphorylation suppresses the development of osimertinib resistance in a preclinical model of EGFR-driven lung adenocarcinoma
2个月前
已完结
皖公网安备34019202002308
